The coronavirus and China’s economy
29 January 2020 | Markets and economy
The coronavirus that is making news for its lethality and rapid spread—and for the selling it has triggered in global stock markets—has a lot in common with the SARS virus that jolted China’s economy in 2003.
But China’s prompt and internationally coordinated response this time may offer some reassurance that the human and economic effects can be limited, according to Qian Wang, Ph.D., Vanguard’s Asia-Pacific chief economist.
As is suspected with the new coronavirus, SARS (severe acute respiratory syndrome, also a coronavirus) started in animals and spread to humans, and quickly became capable of human-to-human transmission. Human contagion coincided with the start of the Chinese New Year, when hundreds of millions travel for China’s most festive season.
SARS killed almost 10% of the more than 8,000 people it sickened, according to the U.S. Centers for Disease Control and Prevention, and most of the deaths were in China. It knocked 2 percentage points off China’s GDP growth in the second quarter of 2003, with transportation, tourism, and hospitality hit especially hard. Those sectors and retail will likely be among the hardest-hit again, Dr. Wang said.
Yet while the situation is likely to get worse before it gets better, Dr. Wang anticipates acute but short-lived harm to China’s growth.
What’s different this time?
The main effect on China’s economic growth will likely be one of sentiment, Dr. Wang said, with the government’s response determining the degree to which people are fearful or confident.
“The good news is that the Chinese government has taken serious actions quickly,” Dr. Wang said. Its disclosure of information and policy responses have vastly improved since the SARS outbreak, she said, and the government has instituted “all-out prevention and control efforts.”
Vanguard therefore has maintained its outlook for China’s 2020 GDP growth at 5.8%, though the risk is clearly tilting toward the downside, Dr. Wang said. While the coronavirus threatens growth in the near term, Vanguard foresees the potential for a rebound in the second half of the year amid anticipated government stimulus.
The spillover to the rest of the world could be limited given a prompt and better-coordinated international public health response this time, Dr. Wang said—though the degree would vary across countries depending on their economic ties with China.
What it means for investors
Investors who saw stock markets continue their 2019 gains into the new year have now seen some of the recent gains evaporate with the coronavirus fears. Our 2020 Vanguard economic and market outlook envisioned such volatility, given heightened policy uncertainties, late-cycle risks, and stretched valuations in some markets.
Just as we guide investors to consider vibrant markets in the context of their goals, we do the same when markets are ailing. Know why you invest, maintain a diversified mix of assets to match those goals, and look beyond a troubled short term.
The contents of this document and any attachments/links contained in this document are for general information only and are not advice. The information does not take into account your specific investment objectives, financial situation and individual needs and is not designed as a substitute for professional advice. You should seek independent professional advice regarding the suitability of an investment product, taking into account your specific investment objectives, financial situation and individual needs before making an investment.
The contents of this document and any attachments/links contained in this document have been prepared in good faith. Please note that the information may have become outdated since its publication, and any information sourced from third parties is not necessarily endorsed by The Vanguard Group, Inc., and all of its subsidiaries and affiliates (collectively, the “Vanguard Entities”).
This document contains links to materials which may have been prepared in the United States and which may have been commissioned by the Vanguard Entities. They are for your information and reference only and they may not represent our views. The materials may include incidental references to products issued by the Vanguard Entities.
The information contained in this document does not constitute an offer or solicitation and may not be treated as an offer or solicitation in any jurisdiction where such an offer or solicitation is against the law, or to anyone to whom it is unlawful to make such an offer or solicitation, or if the person making the offer or solicitation is not qualified to do so. The Vanguard Entities may be unable to facilitate investment for you in any products which may be offered by the Vanguard Group, Inc.
No part of this document or any attachments/links contained in this document may be reproduced in any form, or referred to in any other publication, without express written consent from the Vanguard Entities. Any attachments and any information in the links contained in this document may not be detached from this document and/or be separately made available for distribution.
This document is being made available in Hong Kong by Vanguard Investments Hong Kong Limited (CE No. : AYT820) (“Vanguard Hong Kong”). Vanguard Hong Kong is licensed with the Securities and Futures Commission (“SFC”). The contents of this document have not been reviewed by the Securities and Futures Commission in Hong Kong. Investment involves risk. Past performance is not indicative of future results. Investors are advised to consider their own investment objectives and circumstances. If you are in any doubt, you should seek professional advice.
Copyright, trademark and other forms of proprietary rights protect the contents of this document. You may not copy, publish and/or distribute any derivative works from the information from this document.